Pacific Biomarkers, Inc. Schedules Second Quarter Conference Call for Friday, February 12, 2010

SEATTLE, Feb. 9 /PRNewswire-FirstCall/ -- Pacific Biomarkers, Inc. (OTC Bulletin Board: PBME), which provides specialty reference biomarker services to support pharmaceutical and laboratory diagnostic manufacturers in the conduct of human clinical research, today announced that it has scheduled an investor conference call for 11:15 a.m. EST (8:15 a.m. PST) on Friday, February 12, 2010 to review the Company's operating results for the second quarter and first half of FY2010. The Company intends to report its operating results prior to the conference call.

The Company also announced that its corporate name has been officially changed to Pacific Biomarkers, Inc. The name was approved by shareholders and the State of Washington in December 2009. At the present time, the Company is waiting for a pending change in its stock symbol. In the meantime, the shares continue to trade on the OTC Bulletin Board under the symbol "PBME".

Investor Conference Call

Shareholders and other interested parties may participate in the investor conference call by dialing 800-860-2442 (international/local participants dial 412-858-4600) and requesting participation in the "Pacific Biomarkers, Inc. Conference Call" a few minutes before 11:15 A.m. EST on February 12, 2010. A replay of the conference call will be available one hour after the call through Friday, February 19, 2010 at 5:00 p.m. EDT by dialing 877-344-7529 (international/local participants dial 412-317-0088) and entering the Conference ID # 437808.

About Pacific Biomarkers, Inc. (PBI)

Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies. PBI also provides clinical biomarker services focusing on the emerging field of biomarker assay development and testing. Services include validating and performing ligand-binding assays for novel clinical biomarkers, immunogenicity testing, cell based assay testing and multiplex testing.

PBI is headquartered in Seattle, Washington, and its common stock trades on the OTC Bulletin Board under the symbol "PBME". For more information about PBI, visit the company's web site at www.pacbio.com.

SOURCE Pacific Biomarkers, Inc.